[
    [
        {
            "time": "2018-03-25",
            "original_text": "Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B",
            "features": {
                "keywords": [
                    "Acquisition",
                    "Auris Health",
                    "Johnson & Johnson"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-02-28",
            "original_text": "Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down",
            "features": {
                "keywords": [
                    "Earnings",
                    "Margins Down",
                    "Quest Diagnostics"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-10",
            "original_text": "Baxter's Acute Therapies Profile Strong, Competition Rife",
            "features": {
                "keywords": [
                    "Acute Therapies",
                    "Strong Profile",
                    "Competition"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Baxter's Acute Therapies Profile Strong, Competition Rife",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-02-15",
            "original_text": "Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines",
            "features": {
                "keywords": [
                    "Earnings Beat",
                    "Gross Margin Declines",
                    "Bio-Techne"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-02-26",
            "original_text": "Quidel Corp (QDEL) Q4 2018 Earnings Conference Call Transcript",
            "features": {
                "keywords": [
                    "Earnings",
                    "Conference Call",
                    "Quidel Corp"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Quidel Corp (QDEL) Q4 2018 Earnings Conference Call Transcript",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        }
    ]
]